Research progress in key technologies for quality control of snake venom hemocoagulase drugs

doi:10.19803/j.1672-8629.20230228

Abstract

Abstract: With the wide application of snake venom hemocoagulase in clinical practice in recent years, better quality of its products is required. However, constrained by the complexity of the products and related technologies, it becomes increasingly difficult for the key quality control technologies, especially quality control projects such as structural characterization, purity analysis and potency, to meet the requirements of increasingly stringent quality control. By referring to domestic and foreign pharmacopoeias and the latest research progress in other proteinic drugs, this article summarizes the structural characteristics, purity and potency determination methods of snake venom hemocoagulase drugs before future developments are predicted. It is hoped that this article can be of referential value for the improvement of levels of quality control of hemocoagulase drugs.

Key words: hemocoagulase, quality control, primary structure, advanced structure, purity, activity, snake venom

CLC Number:

LIU Bo, GUO Yunxiao, LIU Lisha, FAN Huihong. Research progress in key technologies for quality control of snake venom hemocoagulase drugs[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1195-1200.

References

[1] CHEN JZ.Research and application of snake venom[J]. Journal of Snake(蛇志), 1989, 1(1) : 22-23.
[2] FU HY, ZHOU L.Research progress of snake venom thrombin[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2008, 43(4) : 245-247.
[3] ICH Expert Working Group. ICH harmonised tripartite guideline specifications : test procedures and acceptance criteria for biotechnological/biological products[EB/OL]. (1993-03-10) [2021-11-08]. https://www.fda.gov/media/71510/download.
[4] TANG YL, HUANG M, HU QP, et al.Agkihpin, a distinct SVTLE from the venom of gloydius halys pallas : purifiation, characterization and structure activity determination[J]. Chemistry&Biodiversity, 2018, 15: e1800122.
[5] XIAN RQ, WANG CC, GONG LP, et al.A species specific strategy forthe Identification of hemocoagulase agkistrodon halys pallas Based on LC-MS/MS-MRM frontiers in molecular biosciences[J]. Original Research, 2022, 9 : 831293.
[6] MIMURA Y, SALDOVA R, MIMURA-KIMURA Y, et al.Micro-heterogeneity of antibody molecules[J]. Antibody Glycosylation, 2021, 112 : 1-26.
[7] GREENFIELD NJ.Using circular dichroism spectra to estimate protein secondary structure[J]. Nat Protoc, 2006, 1(6): 2876-2890.
[8] Chinese Pharmacopoeia Commission.Pharmacopoeia of People's Republic of China 2020
(中华人民共和国药典2020年版)[M]中华人民共和国药典2020年版)[M]. Beijing: China Medical Science Press, 2020.
[9] JIA SH, WANG MM.Separation and purification of haemocoagulase from agkistrodon blomhoffii in Changbai mountain[J]. China Pharmacist(中国药师), 2017, 20(2) : 212-215.
[10] LIU B, ZHANG T, HUANG L, et al.Determination of 7 N-nitrosoamines in metformin hydrochloride sustained release tablets by LC-HRMS[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(5): 454-468.
[11] TAN HP, WANG YJ, ZOU Y, et al.Methods of molecular weight determination of proteins[J]. China Measurement & Test(中国测试), 2011, 37(2): 34-37.
[12] HENRY S, ASISH C, YU Y, et al.Structural characterization of the therapeutic monoclonal antibody trastuzumab by LC /MS and LC /MS^E[J]. Chinese Journal of New Drugs(中国新药杂志), 2014, 23(4) : 418-431.
[13] GUI F, YANG LL, PAN YB, et al.Establishment and validation of an LC/MS peptide mapping method for the characterization of anti-TNF-α monoclonal antibody[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2017, 37(1): 51-63.
[14] WU G, WANG WB, YU CF, et al.Comprehensive characterization of anti-CTLA4 monoclonal antibody by liquid chromatography high resolution mass spectrometry[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2020, 55(6): 457-464.
[15] LIU HL, REN WC, ZONG L, et al.Pepsin digestion combined with post-column online reduction for analysis of disulfide bonds in recombinant human granulocyte stimulating factor[J]. Chinese Journal of Analytical Chemistry(分析化学), 2019, 47(4): 508-518.
[16] KAUR H.Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development[J]. Critical Reviews in Biotechnology, 2021, 41(2): 300-315.
[17] LIU XY, CHANG JL, LIU YL.Current status and progress in research of glycosylation modification of monoclonal antibody[J]. Chinese Journal of Biologicals, 2020, 33(2): 216-221.
[18] LI ML, ZHU WW, ZHANG JL.N-glycans and intact glycopeptide-based characterization of N-glycosylation of monoclonal antibody drugs[J]. Acta Pharmaceutica Sinica(药学学报), 2021, 56(9): 2360-2366.
[19] WANG WB, YU CF, et al.Analysis of N-linked glycan profile of therapeutic antibodies by UPLC-QDA MS[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2018, 53(3): 223-227.
[20] DING J, QIAN JQ.Methods for characterizing the secondary and tertiary structures of proteins[J], Zhejiang Chemical Industry(浙江化工), 2022, 51(11): 49-54.
[21] U.S.Pharmacopoeia Convention. U.S. Pharmacopoeia 43[M]. The United States Pharmacopeial Convention, 2020.
[22] CHENG SY, WANG CZ, LI J, et al.Study on the purity analysis method of hemocoagulase[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2012, 32(8): 1398-1401.
[23] ZHANG XL, CUI Y, CUI AS, et al.Purification and quality of Wusuli haemocoagulase[J]. China Medical Herald(中国医药导报), 2017, 14(1): 20-23.
[24] WANG WB, YU CF, ZHANG F, et al.Establishment of capillary zone electrophoresis method for charge heterogeneity analysis of IgG2 monoclonal antibody[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2018, 53(8): 627-631.
[25] MARK S, CRUZADO-PARK I, CHAPMAN J, et al.A systematic study in CIEF: Defining and optimizing experimental parameters critical to method reproducibility and robustness[J]. Electrophoresis, 2009, 30 : 4049-4058.
[26] LI X, SHI XC, QIN X, et al.Interlaboratory method validation of imaged capillary isoelectric focusing methodology for analysis of recombinant human erythropoietin[J]. Royal Society of Chemistry, 2020,12: 3836-3843.
[27] LIU XL, CHEN L, DENG YP, et al.Application of ion exchange chromatography in protein separation[J]. Feed Research(饲料检测), 2013, 10(3): 71-73.
[28] DU YY, WU FJ, HAN H, et al.Determination of the purity of recombinant human serum albumin interferon α 2b fusion protein using ion exchange HPLC[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2020, 40(8): 1490-1493.
[29] HONG WW, ZHOU FY, FU MJ, et al.Development of a method for determination of purity in tuberculosis therapeutic DNA vaccine based on ion exchange chromatography[J]. Journal of Pharmaceutical Research(药学研究), 2022, 39(11): 628-631.
[30] Pharmaceuticals and Medical Devices Agency of Japan. The Japanese Pharmacopoeia[M]. 17th ed, Tokyo: the Ministry of Health, Labor and Welfare, 2016.
[31] WANG WR, GAO XF, LIU YY, et al.Validation of purity detection for Exendin-4-Fc fusion protein by SEC-HPLC[J]. Progress in Microbiology and Immunology, 2020, 48(5): 16-20.
[32] ZHOU Q, XU MM, ZHAO Q, et al.Determination of purity of antitoxin/antiserum products by high performance size exclusion chromatography[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2021, 38(12): 1484-1489.
[33] LI XL, CUI LL, LI XN, et al.Methodology of a new potency assay of hemocoagulase[J]. Drug Standards of China(中国药品标准), 2018, 19(5): 346-352.
[34] TENG YK, KAN WN.Pontency determination of defibrase by blood coagulation analyzer[J]. China Pharmacist(中国药师), 2012, 15(6): 843-845.